{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:08:02Z","timestamp":1793340482181,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of long-acting injectable antiretroviral therapy (LA-ART) for human immunodeficiency virus (HIV) treatment and prevention is increasing, but there are challenges that could limit broad expansion of these important treatments. The goal of this study was to explore attitudes, barriers, and facilitators for implementing LA-ART administration within community pharmacies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a mixed-methods study focusing on pre-implementation aspects of community pharmacy-administered LA-ART. Pharmacists, clinic staff members, and persons with HIV completed a baseline survey followed by an individual semi-structured qualitative interview with questions based on the Consolidated Framework for Implementation Research (CFIR v.1.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 63 participants (pharmacist\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919, clinic staff\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920, person with HIV\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) from Alabama, California, Florida, and Texas were included in the study. Most pharmacist participants were employed in retail pharmacies that processed fewer than 500 prescriptions per day (75%) and most had more than 10 years of experience working with people with HIV (53%). Clinic staff participants were also highly experienced in working with people with HIV (55%). People with HIV enrolled in the study were either on oral antiretroviral therapy but interested in LA-ART (59%) or were already on LA-ART (29%). Clinics were the preferred location for LA-ART administration while community pharmacy was the second preferred location. Attitudes regarding pharmacy-based administration of LA-ART were mostly positive, with the primary facilitator being positive experiences or established relationships between clinics and pharmacies or persons with HIV and their pharmacies. Barriers included concerns about pharmacy staffing, training, space, privacy, and pharmacy reimbursement for services.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Involving community pharmacies in the administration of LA-ART could expand access to HIV treatment and prevention medications. Outlining best practices that leverage facilitators and overcome barriers can help clinics, pharmacy, and communities expand this novel model of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.Gov Registration: NCT05152953 (posted 12\/10\/2021).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-12971-8","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:03:38Z","timestamp":1749099818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preparing for pharmacy-based delivery of long-acting injectable antiretrovirals: a pre-implementation study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-1939","authenticated-orcid":false,"given":"Jennifer","family":"Cocohoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-4741","authenticated-orcid":false,"given":"Yvette","family":"Cuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-0684","authenticated-orcid":false,"given":"Elizabeth","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5797-7849","authenticated-orcid":false,"given":"George","family":"Udeani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sigua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parya","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"12971_CR1","unstructured":"Gilman B, Bouchery E, Hogan P, Others. The HIV Clinician Workforce in the United States: Supply and Demand Projections from 2010 to 2015. HIV\/AIDS Bureau. 2018. Available from: https:\/\/hab.hrsa.gov\/publications\/library\/hiv-clinician-workforce-united-states. Cited 21 Sep 2021."},{"key":"12971_CR2","unstructured":"Czarnogorski M, Garris C, D\u2019Amico R. CUSTOMIZE: overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable for HIV treatment in US healthcare settings; final patient and provider data. 2021. (virtual). Available from: https:\/\/theprogramme.ias2021.org\/Abstract\/Abstract\/899. Cited 21 Sep 2021."},{"key":"12971_CR3","doi-asserted-by":"publisher","first-page":"e0262926","DOI":"10.1371\/journal.pone.0262926","volume":"17","author":"O Jolayemi","year":"2022","unstructured":"Jolayemi O, Bogart LM, Storholm ED, Goodman-Meza D, Rosenberg-Carlson E, Cohen R et al. O Sued editor 2022 Perspectives on Preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE 17 e0262926.","journal-title":"PLoS ONE"},{"key":"12971_CR4","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of Long-Acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in High-Income countries. Clin Infect Dis. 2022;75:S541\u20138.","journal-title":"Clin Infect Dis"},{"key":"12971_CR5","doi-asserted-by":"publisher","first-page":"e0183172","DOI":"10.1371\/journal.pone.0183172","volume":"12","author":"DM Qato","year":"2017","unstructured":"Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the united states: 2007\u20132015. PLoS ONE. 2017;12:e0183172.","journal-title":"PLoS ONE"},{"key":"12971_CR6","doi-asserted-by":"crossref","unstructured":"Colangeli H. 2074 Analysis of Current Pharmacy Statutes and Regulations Governing Pharmacists\u2019 Authority to Administer Cabotegravir (CAB) for PrEP in the United States (US). Open Forum Infectious Diseases. 2022;9:ofac492.1696.","DOI":"10.1093\/ofid\/ofac492.1696"},{"key":"12971_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/PPA.S30244","volume":"6","author":"P Saberi","year":"2012","unstructured":"Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence. 2012;6:297\u2013322.","journal-title":"Patient Prefer Adherence"},{"key":"12971_CR8","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1016\/j.sapharm.2021.07.020","volume":"18","author":"A Ahmed","year":"2022","unstructured":"Ahmed A, Abdulelah Dujaili J, Rehman IU, Chuah LH, Hashmi FK, Awaisu A, et al. Effect of pharmacist care on clinical outcomes among people living with HIV\/AIDS: A systematic review and meta-analysis. Res Social Administrative Pharm. 2022;18:2962\u201380.","journal-title":"Res Social Administrative Pharm"},{"key":"12971_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0033354920941184","volume":"135","author":"DH McCree","year":"2020","unstructured":"McCree DH, Byrd KK, Johnston M, Gaines M, Weidle PJ. Roles for pharmacists in the ending the HIV epidemic: A plan for America initiative. Public Health Rep. 2020;135:547\u201354.","journal-title":"Public Health Rep"},{"key":"12971_CR10","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.japh.2020.06.005","volume":"60","author":"KA Koester","year":"2020","unstructured":"Koester KA, Saberi P, Fuller SM, Arnold EA, Steward WT. Attitudes about community pharmacy access to HIV prevention medications in California. J Am Pharmacists Association. 2020;60:e179\u201383.","journal-title":"J Am Pharmacists Association"},{"key":"12971_CR11","unstructured":"https:\/\/www.aphafoundation.org\/sites\/default\/files\/ckeditor\/files\/Disha%20Soni.pdf. Available from: https:\/\/www.aphafoundation.org\/sites\/default\/files\/ckeditor\/files\/Disha%20Soni.pdf. Cited 29 Mar 2024."},{"key":"12971_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11577-017-0454-1","volume":"69","author":"J Schoonenboom","year":"2017","unstructured":"Schoonenboom J, Johnson RB. How to construct a mixed methods research design. Kolner Z Soz Sozpsychol. 2017;69:107\u201331.","journal-title":"Kolner Z Soz Sozpsychol"},{"key":"12971_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12874-018-0594-7","volume":"18","author":"K Vasileiou","year":"2018","unstructured":"Vasileiou K, Barnett J, Thorpe S, Young T. Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period. BMC Med Res Methodol. 2018;18:148.","journal-title":"BMC Med Res Methodol"},{"key":"12971_CR14","first-page":"1091","volume":"67","author":"LA Anderson","year":"1990","unstructured":"Anderson LA, Dedrick RF. Development of the trust in physician scale: a measure to assess interpersonal trust in patient-physician relationships. Psychol Rep. 1990;67:1091\u2013100.","journal-title":"Psychol Rep"},{"key":"12971_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","volume":"12","author":"BJ Weiner","year":"2017","unstructured":"Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12:108.","journal-title":"Implement Sci"},{"key":"12971_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.","journal-title":"Implement Sci"},{"key":"12971_CR17","unstructured":"The Consolidated Framework for Implementation Research.\u2013 Technical Assistance for users of the CFIR framework. Available from: https:\/\/cfirguide.org\/. Cited 25 Sep 2021."},{"key":"12971_CR18","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Thematic analysis. 2012. pp. 57\u201371.","DOI":"10.1037\/13620-004"},{"key":"12971_CR19","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods Designs\u2014Principles and practices. Health Serv Res. 2013;48:2134\u201356.","journal-title":"Health Serv Res"},{"key":"12971_CR20","unstructured":"Volume 34| HIV Surveillance| Reports| Resource Library| HIV\/AIDS| CDC. 2023. Available from: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-34\/index.html. Cited 29 Mar 2024."},{"key":"12971_CR21","unstructured":"National Profile| Volume 28 Number 4| HIV Surveillance| Reports| Resource Library| HIV\/AIDS| CDC. 2023. Available from: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-28-no-4\/content\/national-profile.html. Cited 20 Nov 2023."},{"key":"12971_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12879-023-08071-9","volume":"23","author":"L Slama","year":"2023","unstructured":"Slama L, Porcher R, Linard F, Chakvetadze C, Cros A, Carillon S, et al. Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users. BMC Infect Dis. 2023;23:98.","journal-title":"BMC Infect Dis"},{"key":"12971_CR23","doi-asserted-by":"publisher","first-page":"ofac293","DOI":"10.1093\/ofid\/ofac293","volume":"9","author":"KA Christopoulos","year":"2022","unstructured":"Christopoulos KA, Colasanti J, Johnson MO, Diaz Tsuzuki M, Erguera XA, Flores R, et al. Are patients and their providers talking about Long-Acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. Care sites. Open Forum Infect Dis. 2022;9:ofac293.","journal-title":"Open Forum Infect Dis"},{"key":"12971_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","volume":"37","author":"LA Hill","year":"2023","unstructured":"Hill LA, Abulhosn KK, Yin JF, Bamford LP. Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine. AIDS. 2023;37:605\u20139.","journal-title":"AIDS"},{"key":"12971_CR25","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","volume":"76","author":"KA Christopoulos","year":"2023","unstructured":"Christopoulos KA, Grochowski J, Mayorga-Munoz F, Hickey MD, Imbert E, Szumowski JD, et al. First demonstration project of Long-Acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. Clin Infect Dis. 2023;76:e645\u201351.","journal-title":"Clin Infect Dis"},{"key":"12971_CR26","doi-asserted-by":"publisher","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","volume":"9","author":"LF Collins","year":"2022","unstructured":"Collins LF, Corbin-Johnson D, Asrat M, Morton ZP, Dance K, Condra A, et al. Early experience implementing Long-Acting injectable cabotegravir\/rilpivirine for human immunodeficiency Virus-1 treatment at a Ryan White-Funded clinic in the US South. Open Forum Infect Dis. 2022;9:ofac455.","journal-title":"Open Forum Infect Dis"},{"key":"12971_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/apc.2023.0250","volume":"38","author":"NM Nguyen","year":"2024","unstructured":"Nguyen NM, Kavanagh R, Gozar M, Cabral D, Goetz H, Cha A, et al. Implementation of a Pharmacist-Led, Long-Acting, injectable cabotegravir\/rilpivirine program for HIV-1 at health System-Based clinics in the new York metropolitan area. AIDS Patient Care STDS. 2024;38:115\u201322.","journal-title":"AIDS Patient Care STDS"},{"key":"12971_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13012-019-0867-5","volume":"14","author":"NM Weir","year":"2019","unstructured":"Weir NM, Newham R, Dunlop E, Bennie M. Factors influencing National implementation of innovations within community pharmacy: a systematic review applying the consolidated framework for implementation research. Implement Sci. 2019;14:21.","journal-title":"Implement Sci"},{"key":"12971_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/pharmacy11020045","volume":"11","author":"AL Murphy","year":"2023","unstructured":"Murphy AL, Suh S, Gillis L, Morrison J, Gardner DM. Pharmacist administration of Long-Acting injectable antipsychotics to Community-Dwelling patients: A scoping review. Pharmacy. 2023;11:45.","journal-title":"Pharmacy"},{"key":"12971_CR30","doi-asserted-by":"crossref","unstructured":"Mooney EV, Hamper JG, Willis RT, Farinha TL, Ricchetti CA. Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy. J Am Pharm Assoc (2003). 2018;58:S24-S29.e2.","DOI":"10.1016\/j.japh.2018.04.035"},{"key":"12971_CR31","doi-asserted-by":"crossref","unstructured":"Mascari LN, Gatewood SS, Kaefer TN, Nadpara P, Goode J-VR, Crouse E. Evaluation of patient satisfaction and perceptions of a long-acting injectable antipsychotic medication administration service in a community-based pharmacy during the COVID-19 pandemic. J Am Pharm Assoc (2003). 2022;62:S29\u201334.","DOI":"10.1016\/j.japh.2022.01.016"},{"key":"12971_CR32","unstructured":"The impact of pharmacist involvement on immunization uptake. and other outcomes: An updated systematic review and meta-analysis. PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35961937\/. Cited 29 Mar 2024."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12971-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12971-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12971-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:04:30Z","timestamp":1781604270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-025-12971-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12971"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12971-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5708282\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and all participants provided informed consent via electronic signature, after receiving detailed information about the study. This study received IRB approval or a waiver of IRB review from the University of California San Francisco IRB, WCG IRB, Texas University A&M IRB, Auburn University IRB, and Nova Southeastern University IRBs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The University of California San Francisco School of Pharmacy has previously received grant funding from Walgreens. Co which provided salary support for Dr. Cocohoba to conduct research not linked to this study. Dr. Hester has received honoraria for a one-time speaker program sponsored by ViiV Healthcare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"808"}}